A Medical Revolution Facing a Legal Wall
The intersection of Artificial Intelligence (AI) and pharmacology is accelerating the discovery of life-saving drugs, but it is also crashing against traditional legal frameworks. A landmark case involving Insilico Medicine has sparked a global debate on intellectual property.
The company utilized a generative AI platform to identify a promising molecule to fight pulmonary fibrosis—a serious condition where lung tissue becomes scarred, making it difficult to breathe. While Insilico Medicine openly credited their AI for the discovery in press releases, the official patent application told a different story: it omitted the machine entirely and named five human beings, including CEO Alex Zhavoronkov, as the inventors.
The "Human-Only" Rule
According to current US statutes, an inventor must be a "person" (a biological human). This was cemented in 2022 when a Washington DC appeals court rejected the case of DABUS, an AI that sought recognition as the inventor of a food container. The ruling was absolute: machines cannot be inventors.
The USPTO Perspective
The United States Patent and Trademark Office (USPTO) has largely viewed AI as a sophisticated tool—much like a calculator. Under this pragmatic approach, AI does not need to be mentioned in patent applications, simplifying the process but creating a precarious legal vacuum.
The Risks of "Legal Fiction"
Legal experts, including Ryan Abbott, warn that if a patent lists human inventors for a discovery made entirely by AI, the patent could potentially be invalidated. This would create a dangerous domino effect: companies could lose legal protection over their innovations, drastically discouraging investment in R&D.
The Industry's Defense
Companies like Insilico Medicine argue that AI is not working in a vacuum. They maintain that humans are still essential for synthesizing the drug, creating chemical variants, and conducting critical animal testing. By doing so, they aim to preserve human authorship to ensure their discoveries remain protected by law.
"AI is not a calculator; it is a creative partner. Ignoring its role in invention is a legal fiction that will eventually collapse," suggests a sector analyst.
Source: MIT Technology Review